Voyager Acquisition Corp. has entered into an amendment with Veraxa Biotech AG and Oliver Baumann, acting as representative for Veraxa's shareholders, to extend the end date of their previously announced business combination agreement to August 7, 2026. The amendment also removes the requirement for Voyager Acquisition Corp. to pay a termination fee if the agreement is ended under certain conditions. These changes were disclosed in a recent company filing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-25-008292), on October 21, 2025, and is solely responsible for the information contained therein.